Advertisement

International Journal of Clinical Pharmacy

, Volume 33, Issue 1, pp 61–65 | Cite as

Polypharmacy associated with medical tourism: a critique on drug therapy

  • Khalid A. J. Al KhajaEmail author
  • Reginald P. Sequeira
  • Awatif H. H. Damanhori
Case Report

Introduction

Medical tourism is the practice of patients seeking health care services from an area outside their home country. In recent years, medical tourism has rapidly grown for the following reasons: (a) inadequate access to health care services at home country; (b) the treatment is not covered by health insurance providers; (c) the service is available at a much lower cost elsewhere; and (d) long waiting period to get access to care as a result of overburden on public health-care system at home country [1]. Complicated urgent surgeries and elective procedures are the most frequently sought procedures by patients as medical tourists [2].

Polypharmacy is the prescription, administration, or use of more medications than are clinically warranted [3]. Polypharmacy has been shown to predispose patients to drug-drug interactions, adverse drug reactions, and poor patient compliance [4].

We present a case of polypharmacy associated with medical tourism in a middle-aged Bahraini who sought...

Keywords

Metformin Tramadol Rosiglitazone Fenofibrate Pregabalin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

We are grateful to the patient who has given consent for publication of this report. We acknowledge Mr. Mohd Ghali Rashid (Reference Librarian) for information retrieval, and Ms. Radha Raghavan for assistance in preparing this manuscript.

Funding

none.

Conflicts of interests

There is no conflict of interest to declare.

References

  1. 1.
    Pennings G. Ethics without boundaries: medical tourism. In: Ashcroft RE, Dawson A, Draper H, McMillan JR, editors. Principles of health care ethics, 2nd edn. West Sussex, England: Wiley; 2007. Print ISBN: 978 047002 713 4; online ISBN 978 047051 054 4.Google Scholar
  2. 2.
    Horowitz MD, Rosensweig J, Jones CA. Medical trourism: globalization of the healthcare marketplace. Med Gen Med. 2007;9:33.Google Scholar
  3. 3.
    Good CB. Polypharmacy in elderly patients with diabetes. Diabetes Spectr. 2002;15:240–8.CrossRefGoogle Scholar
  4. 4.
    Lee RD. Polypharmacy: a case report and new protocol for management. J Am Board Fam Pract. 1998;11:140–4.PubMedGoogle Scholar
  5. 5.
    Holstein A, Egberts EH. Risk of hypoglycemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes. 2003;111:405–14.PubMedCrossRefGoogle Scholar
  6. 6.
    British National Formulary (BNF)-55: March 2008. BMJ Group and RPS Publishing 2008. Print ISBN: 978 085369 776 3.Google Scholar
  7. 7.
    Martindale. The complete drug reference. Thirty-third edition (ed) Sweetman SC. London: Chicago Pharmaceutical Press; 2002. Print ISBN 0 85369 499 0.Google Scholar
  8. 8.
    Van de Laar FA, Lucassen PL, Akkermans RP, Van de Lisdonk EH, Rutten GE, et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 18: CD003639.Google Scholar
  9. 9.
    Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, et al. Thiazolidinedione use, fluid retention and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256–63.PubMedCrossRefGoogle Scholar
  10. 10.
    Starner CI, Schafer JA, Heaton AH, Gleason PP. Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk warning events. J Manag Care Pharm. 2007;14:523–31.Google Scholar
  11. 11.
    American Diabetes Association. Position statement. Dyslipidemia management in adults with diabetes. Diabetes Care. 2004; 27 (suppl 1): S68–71.Google Scholar
  12. 12.
    Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atovastatin in adults with hypercholesterolemia. Am J Cardiol. 2004;93:1487–94.PubMedCrossRefGoogle Scholar
  13. 13.
    Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on pharmacokinetics and drug interactions. Circulation. 2004;109(23 Suppl 1):11150–7.Google Scholar
  14. 14.
    Robin SJ. Targeting low high-density lipoprotein cholesterol for therapy: lessons from the Veterans affairs high-density lipoprotein interaction trial. Am J Cardiol. 2001;88:19N–23N.CrossRefGoogle Scholar
  15. 15.
    American Diabetes Association. Position statement. Diabetic nephropathy. Diabetes Care. 2002; 25(Suppl 1): S85–9.Google Scholar
  16. 16.
    Jensen TS, Backonja M, Jimenez SH, Tesfaye S, Valensi P, Ziegler D. New perspective on the management of diabetic peripheral neuropathic pain. Diabetes Vasc Dis Res. 2006;3:108–19.CrossRefGoogle Scholar
  17. 17.
    Max MB, Lynch SA, Muir J, Shoaf SE, Smoller B, Dubner R. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N Eng J Med. 1992;326:1287–8.CrossRefGoogle Scholar
  18. 18.
    Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. How far have we came? Diabetes Care. 2008;31(Suppl 2):S255–61.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Khalid A. J. Al Khaja
    • 1
    Email author
  • Reginald P. Sequeira
    • 1
  • Awatif H. H. Damanhori
    • 2
  1. 1.Department of Pharmacology & TherapeuticsArabian Gulf UniversityManamaKingdom of Bahrain
  2. 2.Primary Care, Ministry of HealthManamaKingdom of Bahrain

Personalised recommendations